MUMBAI/NEW DELHI (Reuters) – Slower government approval for testing new medicines is threatening India’s aspirations to be a fast-growing, low-cost hub for clinical trials, and has prompted some drugs firms to shift operations elsewhere, adding to their costs.
read the full story about Slow approvals put India's drug trials industry at risk
Leave a Reply